Evidence map›Paper›PMID 35946040›Full record

ArticleDrug design, development and therapy2022

Effects of Uremic Clearance Granules on p38 MAPK/NF-κB Signaling Pathway, Microbial and Metabolic Profiles in End-Stage Renal Disease Rats Receiving Peritoneal Dialysis.

Xiaosheng Li, Jie Zheng, Jian Wang, Xianhu Tang, Fengxia Zhang, Shufeng Liu, Yunqiang Liao, Xiaoqing Chen, Wenjuan Xie, Yang Tang

Open access · goldAbstract read
In one paragraph

Article in Drug design, development and therapy, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.7field-weighted citation impact, top 16% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 12 citations in OpenAlex.

  1. Article
  2. Article
  3. The microbial metabolite trimethylamine N-oxide and the kidney diseases.Frontiers in cellular and infection microbiology · 2025
    Review
  4. Review
  5. Review
  6. Article
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Xiaosheng LiDepartment of Nephrology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
Jie ZhengDepartment of Nephrology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
Jian WangDepartment of Nephrology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
Xianhu TangDepartment of Nephrology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
Fengxia ZhangDepartment of Nephrology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
Shufeng LiuDepartment of Nephrology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
Yunqiang LiaoFirst Clinical Medical College of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
Xiaoqing ChenDepartment of Nephrology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
Wenjuan XieDepartment of Nephrology, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People's Republic of China.
Yang TangDepartment of Traditional Chinese Medicine, The First Affiliated Hospital of Gannan Medical University, Ganzhou, 341000, People's Republic of China.ORCID 0000-0002-7416-4169
First Affiliated Hospital of Gannan Medical University · CNGannan Medical University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: End-stage renal disease (ESRD) is the final stage of chronic kidney disease (CKD). In the clinic, Uremic Clearance Granules (UCG) are mainly used in the treatment of early CKD and stabilized renal function. However, the benefits and mechanisms of UCG on ESRD remain unclear. Methods: Rats were randomly divided into four groups: sham group, model group, peritoneal dialysis (PD) group and UCG group. Except for the sham-operated group, ESRD was induced by 5/6 nephrectomy in the other three groups. The PD group and UCG group were then subjected to PD. In addition, the UCG group was given UCG by gavage when PD. Changes in body weight and final kidney weight of rats in each group were monitored. HE and Masson staining were performed to confirm the extent of renal fibrosis. Biochemical kits were used to detect blood urea nitrogen (BUN), serum and urine creatinine (Scr, Cre), and urine protein (UPr) levels. ELISA was used to detect the rats' inflammatory responses. qRT-PCR, WB, and IHC were probed to determine the expression levels of NF-κB and MAPK. 16S rDNA sequencing was performed to analyze the composition of gut microbiota in rats. A liquid chromatograph-mass spectrometer was performed to reveal serum metabolomics changes. Results: UCG increased renal volume and body weight, improved renal fibrosis. It enhanced renal function and decreased the levels of BUN, Scr, Upr, Cre, inflammatory responses, as well as NF-κB and MAPK expressions in renal and colon tissues of ESRD rats. The relative abundances of Bacteroidetes and Firmicutes changed in ESRD rats in response to UCG. Serum metabolomics was utilized to identify 70 differentiated metabolites, which were associated with D-glutamine and D-glutamate metabolism, and Phenylalanine metabolism. Conclusion: Our study confirmed that UCG alleviated ESRD by regulating p38 MAPK/NF-κB signaling pathway, microbial and metabolic profiles.

Indexed as

Kidney Failure, ChronicPeritoneal DialysisRenal Insufficiency, ChronicAnimalsBody WeightFibrosisKidneyMetabolomeNF-kappa Bp38 Mitogen-Activated Protein KinasesRatsSignal TransductionNF-kappa Bp38 Mitogen-Activated Protein Kinasesend-stage renal diseasegut microbiotap38 MAPK/NF-κB signaling pathwayuremic clearance granules

Identifiers

PMID35946040
PMCPMC9357387
OpenAlexW4289545626

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.